KRH 3955 hydrochloride

Key Product Details

Product Description

KRH 3955 hydrochloride is a highly potent CXCR4 antagonist (IC₅₀ = 0.61 nM). Displays selectivity for CXCR4 over a range of other CXC receptors. Inhibits replication of HIV-1 viruses in human PBMC (EC₅₀ values are 0.33 to 1.4 nM). Supresses HIV-1 infection in mice. Orally bioavailable.

Product Specifications for KRH 3955 hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for KRH 3955 hydrochloride

The following data is based on the product molecular weight 589.09.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.70 mL	8.49 mL	16.98 mL
5 mM	0.34 mL	1.70 mL	3.40 mL
10 mM	0.17 mL	0.85 mL	1.70 mL
50 mM	0.03 mL	0.17 mL	0.34 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Iwasaki Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci. 2009 PMID: 19245436
• Murakami The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob.Agents Chemother. 2009 PMID: 19451305

Product Documents for KRH 3955 hydrochloride